Immunoglobulin A nephropathyNews & Research
15 curated articles for Immunoglobulin A nephropathy — FDA updates, peer-reviewed research, clinical-trial milestones, and sponsor press releases. Sorted newest-first.
- ImmunoTargets and therapy Apr 27, 2026
New Insights on IgA Nephropathy from the Perspective of Active Lesions and Systemic Inflammatory Responses.
Immunoglobulin A nephropathy (IgAN) is a chronic disease. Active disease typically presents with massive proteinuria and gross hematuria, along with renal pathological features such as mesangial cell proliferation, endothelial cell proliferation, and crescents. Active lesions may achieve remission f...
Why it matters: Recent peer-reviewed research on Immunoglobulin A nephropathy that may be relevant for patients and caregivers.
- Scientific reports Apr 19, 2026
ACSL4 mediates ferroptosis to promote immunoglobulin A nephropathy progression: scRNA-seq analysis.
Immunoglobulin A nephropathy (IgAN), the most prevalent primary glomerular disease, is a major cause of end-stage renal disease. Ferroptosis, a novel cell death mode induced by iron-dependent phospholipid peroxidation, has been implicated in the progression of chronic kidney disease. Whereas, Acyl-C...
Why it matters: Recent peer-reviewed research on Immunoglobulin A nephropathy that may be relevant for patients and caregivers.
- Frontiers in nutrition Apr 2, 2026
Immune-mediated renal injury and cardiometabolic risk in IgA nephropathy: clinical evidence on telitacicept from a scoping review.
Immunoglobulin A nephropathy (IgAN) is not only the most common primary glomerular disease but also a chronic inflammatory condition associated with increased cardiometabolic risk through the cardiorenal axis. Persistent proteinuria and progressive renal dysfunction are linked to adverse cardiovascu...
Why it matters: Recent peer-reviewed research on Immunoglobulin A nephropathy that may be relevant for patients and caregivers.
- Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association Mar 31, 2026
In situ assessment of glomerular C3/C5 convertases indicates ongoing complement activation in IgA nephropathy.
The complement system contributes to the progression of immunoglobulin A nephropathy (IgAN) and offers promising therapeutic targets currently under investigation. Identifying appropriate candidates for these treatments is now critical. Currently, complement activation in IgAN is assessed using immu...
Why it matters: Recent peer-reviewed research on Immunoglobulin A nephropathy that may be relevant for patients and caregivers.
- Autophagy Mar 25, 2026
ESRRA-ATG5-Mediated mitophagy enhances arginine metabolism to alleviate diabetic kidney disease.
Diabetic kidney disease (DKD) is increasingly recognized as a consequence of impaired mitochondrial quality control in renal tubular epithelial cells (TECs). In this study we show that the nuclear receptor ESRRA (estrogen related receptor alpha) transcriptionally activates ATG5 (autophagy related 5)...
Why it matters: Recent peer-reviewed research on Immunoglobulin A nephropathy that may be relevant for patients and caregivers.
- Innere Medizin (Heidelberg, Germany) Mar 25, 2026
[Primary glomerulonephritides].
Primary glomerulonephritides are inflammatory diseases primarily targeting the glomeruli. Clinically, patients may present with glomerular hematuria and a nephritic urinary sediment and/or with high levels of proteinuria and nephrotic syndrome. Arterial hypertension is also frequently observed ...
Why it matters: Recent peer-reviewed research on Immunoglobulin A nephropathy that may be relevant for patients and caregivers.
- Drugs Mar 7, 2026
Metabolic Checkpoints in IgA Nephropathy: From Pathogenesis to Precision Medicine.
Immunoglobulin A nephropathy (IgAN), the most prevalent primary glomerulopathy globally, exhibits intricate pathomechanisms and significant clinical heterogeneity, with up to 50% of patients progressing to kidney failure within 20 years. Contemporary management of IgAN combines causal therapy agains...
Why it matters: Recent peer-reviewed research on Immunoglobulin A nephropathy that may be relevant for patients and caregivers.
- European journal of internal medicine Mar 7, 2026
Left ventricular remodeling in IgA nephropathy: Prognostic implications and clinical correlations.
The determinants and prognosis of left ventricular (LV) geometric remodeling remain uncharacterized in immunoglobulin A nephropathy (IgAN). We investigated the (1) clinicopathological correlates of LV hypertrophy (LVH), (2) longitudinal evolution of LV geometry, and (3) associations of LVH phenotype...
Why it matters: Recent peer-reviewed research on Immunoglobulin A nephropathy that may be relevant for patients and caregivers.
- Frontiers in immunology Mar 6, 2026
Efficacy and safety of telitacicept combined with immunosuppressive therapy for IgA nephropathy: a retrospective multicenter cohort study.
To investigate the efficacy and safety of telitacicept combined with glucocorticoid/mycophenolate mofetil (GM) versus telitacicept in the treatment of immunoglobulin A nephropathy (IgAN). This retrospective, multicenter cohort study enrolled patients aged ≥ 18 years with biopsy-proven IgAN wh...
Why it matters: Recent peer-reviewed research on Immunoglobulin A nephropathy that may be relevant for patients and caregivers.
- Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association Feb 23, 2026
How should we measure and interpret glomerular inflammation and what is the best anti-inflammatory approach in IgA nephropathy?
Immunoglobulin A nephropathy (IgAN) is the most common primary glomerulonephritis worldwide. The pathogenesis of IgAN is complex, characterized by gut mucosa-kidney interactions that lead to the production of galactose-deficient IgA1 and formation of immune complexes with antiglycan antibodies. Both...
Why it matters: Recent peer-reviewed research on Immunoglobulin A nephropathy that may be relevant for patients and caregivers.
- Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association Feb 23, 2026
What do clinical trials teach us about the pathophysiology of human IgA nephropathy?
Immunoglobulin A nephropathy (IgAN) is a primary glomerulonephritis characterized by IgA-dominant or co-dominant mesangial immune deposits seen on routine immunofluorescence staining of kidney biopsy tissue. Approximately 40% of patients develop kidney failure within 10 years of diagnosis. IgAN...
Why it matters: Recent peer-reviewed research on Immunoglobulin A nephropathy that may be relevant for patients and caregivers.
- Clinical kidney journal Feb 18, 2026
Microscopic hematuria in IgA nephropathy: a biomarker of disease activity.
Immunoglobulin A nephropathy (IgAN) is an immune-mediated disease of B-cell origin and the most common primary glomerulonephritis worldwide, which often progresses to kidney failure within 10-20 years of diagnosis. Microscopic hematuria is frequently observed in IgAN; it is thought to result from da...
Why it matters: Recent peer-reviewed research on Immunoglobulin A nephropathy that may be relevant for patients and caregivers.
- Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association Jan 30, 2026
Targeted therapeutic options based on the pathogenesis of IgA nephropathy.
Immunoglobulin A nephropathy (IgAN) remains the leading cause of primary glomerular disease globally. The disease often results in progressive chronic kidney disease and eventual kidney failure, and has a poor prognosis, significantly increasing the global healthcare burden. The pathogenesis of IgAN...
Why it matters: Recent peer-reviewed research on Immunoglobulin A nephropathy that may be relevant for patients and caregivers.
- Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association Jan 30, 2026
Attribute-based medicine for IgA nephropathy: risk factor constellations influence kidney prognosis.
Attribute-based medicine emphasizes tailoring care to patient-specific characteristics. Immunoglobulin A nephropathy (IgAN), a heterogeneous glomerular disease, presents varying risks across subgroups. We hypothesized that an attribute-based medicine approach could identify residual risk factors and...
Why it matters: Recent peer-reviewed research on Immunoglobulin A nephropathy that may be relevant for patients and caregivers.
- BreakingFDA Sep 15, 2025
Filspari Approved for IgA Nephropathy
The FDA approved Filspari (sparsentan), a dual endothelin and angiotensin receptor antagonist, for IgA nephropathy at risk of disease progression.
Why it matters: First disease-modifying therapy specifically for IgA Nephropathy. Landmark for rare kidney diseases.
More on Immunoglobulin A nephropathy
Articles aggregated from peer-reviewed journals (PubMed), sponsor press releases, SEC 8-K filings, and FDA announcements. Original-source links are preserved on each article page. Editorial tags (Breaking / Notable / Update) reflect UniteRare's curation-time priority assessment.